PDCD1 and neoplasm: Notably, cytokine mRNA triplet exhibited superior anti-tumor activity compared with anti-PD-1 therapy (37.2% TGI at day 20 after the first treatment), which is an ICB therapy used as a standard treatment for several solid tumor indications (Figure 4D).